Related Experiment Video

Updated: May 26, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Predictors of response to targeted therapy in renal cell carcinoma

Laurie J Eisengart1, Gary R MacVicar, Ximing J Yang

  • 1Department of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 E Huron St, Chicago, IL 60611, USA.

Archives of Pathology & Laboratory Medicine
|January 11, 2012
PubMed
Abstract

Insights

Targeted therapies offer improved survival for metastatic renal cell carcinoma patients compared to traditional treatments. Biomarkers show promise for personalizing treatment selection and improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) has a poor prognosis, with a 5-year survival rate around 10%.
  • High-dose interleukin 2 therapy for RCC is limited by severe toxicity.
  • Advances in understanding RCC molecular pathogenesis have led to targeted therapies with better efficacy and safety profiles.

Purpose of the Study:

  • To elucidate the molecular mechanisms of vascular endothelial growth factor inhibitor (antiangiogenic) and mammalian target of rapamycin (mTOR) inhibitor therapies in RCC.
  • To review clinical trial data supporting the effectiveness of these targeted agents in RCC treatment.
  • To identify and describe biomarkers associated with patient outcomes in targeted therapy for RCC.

Main Methods:

  • Literature search of peer-reviewed journals indexed in PubMed (US National Library of Medicine).

Main Results:

  • Vascular endothelial growth factor inhibitor (antiangiogenic) and mammalian target of rapamycin (mTOR) inhibitor therapies demonstrate improved survival and tolerability in RCC.
  • Clinical trials confirm the efficacy of targeted agents in managing metastatic renal cell carcinoma.
  • Specific biomarkers are emerging as predictors of individual patient response to targeted therapies.

Conclusions:

  • Targeted therapies represent a significant advancement in treating metastatic renal cell carcinoma.
  • Biomarker discovery is crucial for developing personalized treatment strategies in RCC.
  • Future research focusing on predictive biomarkers will enable tailored therapeutic approaches for improved patient outcomes.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...